Amylin
A pancreatic peptide co-secreted with insulin that slows gastric emptying and reduces glucagon
Definition
Amylin is a 37-amino-acid peptide co-secreted with insulin by pancreatic β-cells. It slows gastric emptying, reduces glucagon, and promotes satiety. Pramlintide is the FDA-approved synthetic amylin analog for type-1 diabetes. Cagrilintide — a longer-acting analog being developed alongside semaglutide as CagriSema — is the next-generation addition to the incretin-adjacent weight-management pipeline.
Read More
GLP-1 Receptor AgonistGLP-1 RA
A peptide drug class that mimics glucagon-like peptide-1 to slow gastric emptying, sharpen insulin response and quiet food-noise.
PeptideSemaglutideOzempic
A long-acting GLP-1 receptor agonist used for type-2 diabetes and chronic weight management — the active ingredient in Ozempic and Wegovy.
PeptideCagriSema
A dual-peptide combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) — investigational for weight management.
$149 panel.
A clinician reads it in 24 hours.
Order the Peptide Readiness Panel, draw at a Quest or LabCorp near you, and your clinician sends back a matched protocol with a confidence score.